HomeNewsDrug Discovery & Development

Glenmark Pharma launches Bumetanide Injection in single and multi-dose vials

Glenmark Pharma launches Bumetanide Injection in single and multi-dose vials

Glenmark Pharmaceuticals, USA (Glenmark) has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals.

Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy said, “We are pleased to bring to market a lower-cost alternative to

Bumex Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”

More news about: drug discovery & development | Published by Sudeep Soparkar | January - 11 - 2023

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology